Search Result

Results for "

BET degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Androgen Receptor (4) Apoptosis (9) Autophagy (5) c-Myc (4) CDK (1) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (10) Epigenetic Reader Domain (48) FKBP (2) Hedgehog (1) Ligands for E3 Ligase (6) Ligands for Target Protein for PROTAC (9) MDM-2/p53 (1) PARP (1) PD-1/PD-L1 (2) PROTAC Linkers (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (34) Reference Standards (1) Target Protein Ligand-Linker Conjugates (2)
By Research Areas:	Cancer (62) Neurological Disease (1)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-78695

JQ-1 carboxylic acid Maximum Cited Publications 9 Publications Verification	Epigenetic Reader Domain PD-1/PD-L1 Ligands for Target Protein for PROTAC Androgen Receptor	Cancer
JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.

HY-112078

(S,R,S)-AHPC-Me VHL ligand 2; E3 ligase Ligand 1A	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM .

HY-42424

(S,R,S)-AHPC-Me hydrochloride VHL ligand 2 hydrochloride; E3 ligase Ligand 1	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM .

HY-141438

SIM1 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
SIM1 is a potent von Hippel-Lindau (VHL)-based trivalent PROTAC capable of degradation for all *BET* family members, with preference for BRD2 degradation (IC₅₀=1.1 nM; Kd=186 nM). SIM1 shows sustained anti-cancer activity .

HY-129937A

GNE-987 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
GNE-987 is a VHL-dependent BRD4 PROTAC degrader. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC₅₀=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC₅₀=4.7 and 4.4 nM, respectively). GNE-987 can be used for the research of cancer .

HY-114407

TD-428	PROTACs Epigenetic Reader Domain	Cancer
TD-428 is a PROTAC connected by ligands for Cereblon and BRD4. TD-428 is a highly specific BRD4 degrader with a DC₅₀ of 0.32 nM . TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation .

HY-112718

*PROTAC BET* Degrader-10**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-10 (dBET37) is a potent BET protein BRD4 degrader, connected by ligands for Cereblon and BRD4, with a DC₅₀ of 49 nM .

HY-103633

*PROTAC BET* Degrader-1** 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-1 is a PROTAC connected by ligands for Cereblon and *BET*, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.

HY-103634

dFKBP-1 1 Publications Verification	PROTACs FKBP	Cancer
dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of FKBP12, the Thalidomide based Cereblon ligand and a linker .

HY-117690

dBRD9	PROTACs Epigenetic Reader Domain	Cancer
dBRD9,a PROTAC, can selective degrades BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole *BET* family .

HY-123941

FKBP12 PROTAC dTAG-7 3 Publications Verification dTAG-7	PROTACs FKBP Epigenetic Reader Domain	Cancer
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional PROTAC degrader. FKBP12 PROTAC dTAG-7 targets FKBP12 ^F36V and BET BRD4. FKBP12 PROTAC dTAG-7 enables rapid and selective degradation of target proteins, and is suitable for cellular and in vivo studies to analyze protein functions and validate targets .

HY-112429

HJB97 2 Publications Verification	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
HJB97 is a high-affinity *BET* inhibitor with K_i values of 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), and 1.0 nM (BRD4 BD2) . HJB97 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC BET degraders with antitumor activity . HJB97 can be used for the synthesis of BETd-260 (HY-101519).

HY-114229

*PROTAC BET* degrader-3** 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-3 is a PROTAC connected by ligands for von Hippel-Lindau and *BET*.

HY-158764

*PROTAC BET* Degrader-12**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-12 (Compound 8b) is a PROTAC degrader for bromodomain and extra-terminal domain (BET)-containing proteins, which degrades the BRD3 and BRD4 in a DCAF11-dependent manner. PROTAC BET Degrader-12 inhibits cell viability of KBM7 with a DC₅₀ of 305.2 nM

HY-129938

GNE-987 GSH linker-1	PROTAC-Linker Conjugates for PAC	Cancer
GNE-987 GSH linker-1, a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 (HY-129937A) and disulfide-containing linker. GNE-987 GSH linker-1 remains inactive as a degrader until intracellular release of GNE-987 via disulfide reduction and linker self-immolation. GNE-987 GSH linker-1 can be used for the research of acute myeloid leukemia .

HY-145125

SJ995973	PROTACs Epigenetic Reader Domain	Others
SJ995973 (PROTAC) is a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins.

HY-145264

OARV-771	Epigenetic Reader Domain PROTACs	Cancer
OARV-771 is a VHL-based *BET* degrader (PROTAC) with improved cell permeability. OARV-771 shows DC₅₀s of 6, 1, and 4 nM for Brd4, Brd2 and Brd3, respectively .

HY-135250B

Thalidomide-4-O-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-4-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 ^F36V and BET .

HY-147046

ET-JQ1-OH	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
ET-JQ1-OH is an allele-specific BET inhibitor. ET-JQ1-OH can serve as a Ligand for Target Protein for PROTAC, and is used for the development and design of PROTAC Brd4 degraders, such as AB3145 (HY-180923).

HY-131318

Lenalidomide-I	Ligands for E3 Ligase	Cancer
Lenalidomide-I (Compound 72), an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, is used in the recruitment of CRBN protein. Lenalidomide-I can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BET degrader QCA570 (HY-112609) .

HY-123911

dBET23	PROTACs Epigenetic Reader Domain	Cancer
dBET23 is a highly effective and selective PROTAC BRD4 degrader with a DC_50/5h of ~ 50 nM for BRD4_BD1 protein .

HY-42424A

(S,R,S)-AHPC-Me dihydrochloride VHL ligand 2 dihydrochloride; E3 ligase Ligand 1 dihydrochloride	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein . (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC₅₀ <1 nM .

HY-44103

Desmethyl-QCA276 PROTAC BRD4-binding moiety 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade *BET. QCA276 is a BET* inhibitor with an IC₅₀ of 10 nM, and with a K_i of 2.3 nM . Desmethyl-QCA276 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-168546

CFT-1297	PROTACs Epigenetic Reader Domain	Cancer
CFT-1297 is a BET PROTAC degrader that can degrade BRD4 .

HY-114228

*PROTAC BET* degrader-2** 2 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET degrader-2 is a PROTAC connected by ligands for Cereblon and *BET* with an IC₅₀ value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.

HY-161346

EBET-1055	PROTACs Epigenetic Reader Domain	Cancer
EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .

HY-161346A

(Rac)-EBET-1055	PROTACs Epigenetic Reader Domain	Cancer
(Rac)-EBET-1055 is the racemate of EBET-1055 (HY-161346). EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .

HY-130612

*PROTAC BRD2/BRD4 degrader-1*	Epigenetic Reader Domain PROTACs	Cancer
PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader, connected by ligands for Cereblon and *BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. PROTAC BRD2/BRD4 degrader*-1 effectively inhibits solid tumors with low cytotoxic effect .

HY-175354

*PROTAC BET* Degrader-13**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-13 (Compound 34) is a TRIM21-based PROTAC (TRIMTAC) degrader targeting *BET. PROTAC BET* Degrader-13 significantly degrades PML-eGFP-BRD4 fusion protein with a near-complete loss of EGFP+ nuclear puncta with an EC₅₀ of 1.4 μM . Pink: BET ligand (HY-13030); Blue: E3 ligase ligand (HY-W1125585); Black: linker

HY-130813

BET-IN-6	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
BET-IN-6 is a potent and high affnity BRD2/BRD4 inhibitor. BET-IN-6 is the ligand for target protein BRD2/4, and is used for the systhesis of PROTAC BRD2/BRD4 degrader-1 (HY-130612) .

HY-170900

SJ44236	PROTACs Epigenetic Reader Domain c-Myc MDM-2/p53	Neurological Disease Cancer
SJ44236 is a BET PROTAC degrader with activity against BRD2, BRD3 and BRD4 (DC₅₀ = 127 pM). SJ44236 induces ubiquitination and proteasomal degradation by forming a ternary complex with BET proteins and CRBN-DDB1. SJ44236 downregulates c-Myc, upregulates p53 and reduces cancer cell viability. SJ44236 can be used for the research of leukemia and medulloblastoma .

HY-157426

*PROTAC BET* Degrader-19**	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BET Degrader-19 (Pro-2) is a CRBN-based PROTAC degrader for BRD, with a DC₅₀ of 21.1 nM (4h) .

HY-157491

K2-B4-5e	PROTACs Androgen Receptor Epigenetic Reader Domain	Cancer
K2-B4-5e is a E3 ligase KLHDC2-based BRD4 and androgen receptor (AR) degradation PROTAC. K2-B4-5e is capable of inducing rapid and robust degradation of BET-family and AR proteins in cells .

HY-111978

ZEN-3862	Epigenetic Reader Domain	Cancer
ZEN-3862 is a *BET* inhibitor with IC₅₀s of 0.16 and 0.13 μM for BRD4(BD1) and BRD4(BD2) , respectively. ZEN-3862 can be used to form PROTACs to induce degradation of BRD4 .

HY-78695A

(R)-JQ-1 carboxylic acid	Drug Isomer Epigenetic Reader Domain PD-1/PD-L1	Cancer
(R)-JQ-1 carboxylic acid, is an isomer of JQ-1 carboxylic acid (HY-78695). JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.

HY-111977

ZEN-3219	Epigenetic Reader Domain	Cancer
ZEN-3219 is a *BET* inhibitor with IC₅₀s of 0.48, 0.16 and 0.47 μM for BRD4(BD1), BRD4(BD2) and BRD4(BD1BD2), respectively. ZEN-3219 can be used to form PROTACs to induce degradation of BRD4 .

HY-111979

ZEN-3411	Epigenetic Reader Domain	Cancer
ZEN-3411 is a *BET* inhibitor with IC₅₀s of 0.05, 0.05 and 0.06 μM for BRD4(BD1), BRD4(BD2) and BRD4(BD1BD2), respectively. ZEN-3411 can be used to form PROTACs to induce degradation of BRD4 .

HY-122703

BETi-211	Epigenetic Reader Domain Ligands for Target Protein for PROTAC	Cancer
BETi-211 is an orally active *BET* inhibitor (K_i: <1 nM). BETi-211 inhibits growth of triple-negative breast cancers (TNBC) cell lines with IC₅₀ < 1 μM. BETi-211 degrades BET proteins and suppress tumor growth in xenograft breast tumors .

HY-160262

*PROTAC AR/BET* protein degrader-1**	Androgen Receptor PROTACs Epigenetic Reader Domain	Cancer
PROTAC AR/BET protein degrader-1 (Compound 149) is an Androgen Receptor and *BET* (bromodomain and extra-terminal domain) protein degrader that can be used in cancer research .

HY-156814

HPP-9	Hedgehog	Cancer
HPP-9 is a Proteolysis-Targeting Chimeras （PROTACs） based on Hedgehog Pathway Inhibitor-1 (HPI-1), with the pIC₅₀ of 6.71, that can degrade BET bromodomains. HPP-9 has antitumor activity ^[1[.

HY-W1120221

Lenalidomide-C3-NH2	E3 Ligase Ligand-Linker Conjugates	Others
Lenalidomide-C3-NH2 is an E3 ligase ligand-linker conjugate that incorporates the Lenalidomide (HY-A0003) based CRBN ligand (HY-43722) and linker. Lenalidomide-C3-NH2 can be used for synthesis of PROTAC BET degrader-2 (HY-114228) .

HY-130814

Thalidomide-NH-C4-NH2 TFA	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader .

HY-135250A

Thalidomide-4-O-C6-NH2 TFA	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-4-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12 ^F36V and BET .

HY-170390

AB3067	PROTACs Epigenetic Reader Domain	Cancer
AB3067 is a PROTAC degrader for BET protein, that recruits two different E3 ligase Cereblon and VHL with good affinity (IC₅₀=559 nM for VHL in live HEK293; IC₅₀=190 nM for CRBN in live HEK293), and degrades BRD2, BRD3, BRD4 and CRBN with DC₅₀ of 2.1~2.3, 1.6, 15 and 75 nM, respectively. AB3067 inhibits the proliferation of RKO cell with an EC₅₀ of 111 nM .

HY-172562

BTR2004	PROTACs Epigenetic Reader Domain	Cancer
BTR2004 is a selective BET family (BRD2/3/4) protein PROTAC degrader. BTR2004 forms a ternary complex with BRD proteins and KLHL20, inducing ubiquitination and proteasomal degradation through the UPS pathway. BTR2004 is promising for research of PC3 prostate cancer and MDA-MB-231 breast cancer cell lines. Pink: (+)-JQ1-OH (HY-161125); Blue: BTR2000 (HY-172563); Black: Linker (HY-W015236) .

HY-129937

(S)-GNE-987	PROTACs Epigenetic Reader Domain	Cancer
(S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein. (S)-GNE-987 binds to the BRD4 BD1(IC₅₀=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC) .

HY-145177

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc can be used for the synthesis of PROTAC BET degrader . (From patent WO2017180417A1 compound s7).

HY-179588

*PROTAC BET* Degrader-14**	PROTACs Epigenetic Reader Domain c-Myc	Cancer
PROTAC BET Degrader-14 is a highly efficient PROTAC targeting *BET* (bromodomain and extra-terminal domain). PROTAC BET Degrader-14 can degrade all BET (BRD2, BRD3, BRD4) family proteins. PROTAC BET Degrader-14 potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC₅₀ = 130 nM) and KYSE180 esophageal squamous cell carcinoma cell lines (DC₅₀ = 40 nM). PROTAC BET Degrader-14’s dependence on the ubiquitin-proteasome system. PROTAC BET Degrader-14 decreases levels of BET-regulated gene products c-Myc, RUNX2, and KRT14. PROTAC BET Degrader-14 can be used for the study of osteosarcoma .

HY-181867

*PROTAC BET* Degrader-16**	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BET Degrader-16 (Compound A10) is a *BET* PROTAC degrader with a DC₅₀ of 0.31 nM against BRD4, and it preferentially targets BRD4 over other BET family members. PROTAC BET Degrader-16 degrades BRD2, BRD3 and BRD4 via the ubiquitin-proteasome system, a process that requires target binding and recruitment of the CRBN E3 ligase. PROTAC BET Degrader-16 induces cell cycle arrest and promotes apoptosis. PROTAC BET Degrader-16 exerts anti-tumor activity against acute myeloid leukemia .

HY-184335

*PROTAC BET* Degrader-18**	PROTACs Epigenetic Reader Domain c-Myc Apoptosis	Cancer
PROTAC BET Degrader-18 is a PROTAC targeting *BET, with a DC₅₀* of 0.676 nM in HEK293-BRD4-HiBiT-KI cells. PROTAC BET Degrader-18 mainly targets and degrades BRD4 (EC₅₀ = 59.91 nM), and exhibits weak degradation activity against BRD2. PROTAC BET Degrader-18 inhibits the expression of downstream oncoprotein c-Myc, thereby inducing cell cycle arrest and apoptosis, while suppressing oncoprotein expression. PROTAC BET Degrader-18 shows antiproliferative activity against acute myeloid leukemia cells and triple-negative breast cancer cells. PROTAC BET Degrader-18 demonstrates antitumor efficacy in xenograft mouse models. PROTAC BET Degrader-18 can be used for the research of acute myeloid leukemia and triple-negative breast cancer .

Cat. No.	Product Name

HY-L129

Target Protein Ligand Library

96 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 96 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Cat. No.	Product Name		Classification

HY-44103

Desmethyl-QCA276 PROTAC BRD4-binding moiety 4		PROTAC Synthesis
Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade *BET. QCA276 is a BET* inhibitor with an IC₅₀ of 10 nM, and with a K_i of 2.3 nM . Desmethyl-QCA276 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-184537

Desmethyl-QCA276-C3-alkyne		Alkynes
Desmethyl-QCA276-C3-alkyne (Compound 71) is a Target Protein Ligand-Linker Conjugate, composed of the BET ligand Desmethyl-QCA276 (HY-44103) and the PROTAC linker (HY-W035972). Desmethyl-QCA276-C3-alkyne is applicable for the synthesis of the PROTAC QCA570 (HY-112609). Desmethyl-QCA276-C3-alkyne is used in cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: